Direct Oral Anticoagulants: A Quick Guide

Overview

Journal Eur Cardiol

Specialty Cardiology & Vascular Diseases

Date 2018 Nov 13

PMID 30416551

Citations 47

Authors

Sikorska Julia

Uprichard James

Affiliations

Soon will be listed here.

Abstract

Vitamin K antagonists, such as warfarin, have been the anticoagulants of choice for many years for patients with AF and other thrombotic conditions. The introduction of direct oral anticoagulants (DOACs) as alternatives represents a major advance in anticoagulation. DOACs have been found to be at least as safe and effective as vitamin K antagonists in randomised, controlled trials for stroke prevention in AF and the management of venous thromboembolism, with real-world data showing similar outcomes. With the availability of several agents, selecting the most appropriate DOAC can be challenging. The aim of the present article is to provide useful guidance on the implementation of DOAC treatment in clinical practice.

Citing Articles

Effectiveness and Safety in Patients with Non-Valvular Atrial Fibrillation Who Switched from Warfarin to Direct Oral Anticoagulants in Medicare Population.

Atreja N, Dubey A, Kang A, Jiang J, Hagan M, Michael-Asalu A Adv Ther. 2025; 42(3):1462-1483.

PMID: 39883308 PMC: 11868198. DOI: 10.1007/s12325-024-03099-y.

Implementation of a Telemedicine Direct Oral Anticoagulant Monitoring Program at a Safety-Net Hospital.

Cohen Kaplon S, Aqtash S, Gilbride D, Chan C, Farjo R Hosp Pharm. 2024; :00185787241293356.

PMID: 39544828 PMC: 11559874. DOI: 10.1177/00185787241293356.

2022 CVS Caremark DOAC non-medical switch: Patient ramifications and physician advocacy.

Patel K, Patel D, Deison H, Gough R Am J Prev Cardiol. 2024; 20:100870.

PMID: 39430430 PMC: 11489067. DOI: 10.1016/j.ajpc.2024.100870.

Efficacy and Safety of Andexanet Alfa Versus Four Factor Prothrombin Complex Concentrate for Emergent Reversal of Factor Xa Inhibitor Associated Intracranial Hemorrhage: A Systematic Review and Meta-Analysis.

Sarhan K, Mohamed R, Elmahdi R, Mohsen Y, Elsayed A, Zayed D Neurocrit Care. 2024; .

PMID: 39379749 DOI: 10.1007/s12028-024-02130-y.

Dicloxacillin is an inducer of intestinal P-glycoprotein but neither dicloxacillin nor flucloxacillin increases the risk of stroke/systemic embolism in direct oral anticoagulant users.

Iversen D, Dalgard Dunvald A, Ernst M, Abtahi S, Souverein P, Klungel O Br J Clin Pharmacol. 2024; 90(12):3252-3262.

PMID: 39160000 PMC: 11602906. DOI: 10.1111/bcp.16190.

References

Kitchen S, Gray E, Mackie I, Baglin T, Makris M . Measurement of non-coumarin anticoagulants and their effects on tests of Haemostasis: Guidance from the British Committee for Standards in Haematology. Br J Haematol. 2014; 166(6):830-41. DOI: 10.1111/bjh.12975. View

Savarese G, Giugliano R, Rosano G, McMurray J, Magnani G, Filippatos G . Efficacy and Safety of Novel Oral Anticoagulants in Patients With Atrial Fibrillation and Heart Failure: A Meta-Analysis. JACC Heart Fail. 2016; 4(11):870-880. DOI: 10.1016/j.jchf.2016.07.012. View

Young A, Phillips J, Hancocks H, Hill C, Joshi N, Marshall A . OC-11 - Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. Thromb Res. 2016; 140 Suppl 1:S172-3. DOI: 10.1016/S0049-3848(16)30128-1. View

Raccah B, Perlman A, Danenberg H, Pollak A, Muszkat M, Matok I . Major Bleeding and Hemorrhagic Stroke With Direct Oral Anticoagulants in Patients With Renal Failure: Systematic Review and Meta-Analysis of Randomized Trials. Chest. 2016; 149(6):1516-24. DOI: 10.1016/j.chest.2015.12.029. View

Camm A, Amarenco P, Haas S, Hess S, Kirchhof P, Kuhls S . XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J. 2015; 37(14):1145-53. PMC: 4823634. DOI: 10.1093/eurheartj/ehv466. View

Gibson C, Mehran R, Bode C, Halperin J, Verheugt F, Wildgoose P . Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med. 2016; 375(25):2423-2434. DOI: 10.1056/NEJMoa1611594. View

Graham D, Reichman M, Wernecke M, Zhang R, Southworth M, Levenson M . Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation. 2014; 131(2):157-64. DOI: 10.1161/CIRCULATIONAHA.114.012061. View

Eikelboom J, Connolly S, Brueckmann M, Granger C, Kappetein A, Mack M . Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013; 369(13):1206-14. DOI: 10.1056/NEJMoa1300615. View

Yavuz B, Ayturk M, Ozkan S, Ozturk M, Topaloglu C, Aksoy H . A real world data of dabigatran etexilate: multicenter registry of oral anticoagulants in nonvalvular atrial fibrillation. J Thromb Thrombolysis. 2016; 42(3):399-404. DOI: 10.1007/s11239-016-1361-4. View

10.

Granger C, Alexander J, McMurray J, Lopes R, Hylek E, Hanna M . Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365(11):981-92. DOI: 10.1056/NEJMoa1107039. View

11.

Cuker A, Siegal D, Crowther M, Garcia D . Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol. 2014; 64(11):1128-39. PMC: 4167772. DOI: 10.1016/j.jacc.2014.05.065. View

12.

Barnes G, Ageno W, Ansell J, Kaatz S . Recommendation on the nomenclature for oral anticoagulants: communication from the SSC of the ISTH: reply. J Thromb Haemost. 2015; 13(11):2132-3. DOI: 10.1111/jth.13136. View

13.

Bohula E, Giugliano R, Ruff C, Kuder J, Murphy S, Antman E . Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial. Circulation. 2016; 134(1):24-36. DOI: 10.1161/CIRCULATIONAHA.116.022361. View

14.

Connolly S, Ezekowitz M, Yusuf S, Eikelboom J, Oldgren J, Parekh A . Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361(12):1139-51. DOI: 10.1056/NEJMoa0905561. View

15.

Short N, Connors J . New oral anticoagulants and the cancer patient. Oncologist. 2013; 19(1):82-93. PMC: 3903061. DOI: 10.1634/theoncologist.2013-0239. View

16.

Bapat P, Kedar R, Lubetsky A, Matlow J, Aleksa K, Berger H . Transfer of dabigatran and dabigatran etexilate mesylate across the dually perfused human placenta. Obstet Gynecol. 2014; 123(6):1256-1261. DOI: 10.1097/AOG.0000000000000277. View

17.

Mega J, Braunwald E, Wiviott S, Bassand J, Bhatt D, Bode C . Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2011; 366(1):9-19. DOI: 10.1056/NEJMoa1112277. View

18.

Giugliano R, Ruff C, Braunwald E, Murphy S, Wiviott S, Halperin J . Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013; 369(22):2093-104. DOI: 10.1056/NEJMoa1310907. View

19.

Ruff C, Giugliano R, Antman E . Management of Bleeding With Non-Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal Agents. Circulation. 2016; 134(3):248-61. DOI: 10.1161/CIRCULATIONAHA.116.021831. View

20.

Stanton B, Barasch N, Tellor K . Comparison of the Safety and Effectiveness of Apixaban versus Warfarin in Patients with Severe Renal Impairment. Pharmacotherapy. 2017; 37(4):412-419. DOI: 10.1002/phar.1905. View